#ESMO26 Presidential Session presentation for DASL-HiCAP (ANZUP1801) @niazi_Dr7 @urotoday
⚡️MFS-CI Primary Endpoint: HR 0.42, 95%CI 0.27-0.66
⚡️All secondary endpoints favoring addition of Daro
⚡️Limited additional toxicity by adding Daro
105 浏览 · 2 赞 · 1 转发 · 0 回复
Darolutamide with androgen deprivation therapy (ADT) and definitive or salvage locoregional radiation therapy (RT) for localised, very high-risk prostate cancer: Interim analysis of an international, placebo-controlled, randomised phase 3 t
https://esmocongress.esmo.orgINTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgPerioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org⚡️LBA4⚡️ DASL-HiCaP (ANZUP1801) Ph 3 RCT #ESMO26 Daro + ADT and definitive/salvage locoregional RT for very HR PCa @urotoday 🚨n=1,106; mFU 3.8 yrs; 85% definitive RT 🚨Primary EP MFS by CI: ⏫ for Daro vs PBO - 4-year MFS-CI 95% vs 88% - HR 0.42 (95% CI 0.27 to 0.66)在 X 查看被引用的帖子
来源：Zach Klaassen · x.com